https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-awarded-46-mnok-in-innovation-funding/ 2019-07-02T08:46:27+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_sept_7th_standin-e1591090134293.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-signs-distribution-agreement-with-radiopharmaceutical-wholesaler/ 2019-07-02T08:46:50+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/full_radspherin.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-and-attend-the-32nd-annual-congress-of-the-european-association-of-nuclear-medicine/ 2019-07-02T08:47:02+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_aug_12th_2.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-researcher-presents-findings-at-snmmi-annual-meeting-in-philadelphia/ 2019-07-02T08:47:14+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/Elisa2.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-receive-12-mnok-in-bia-funding-from-the-research-council-of-norway/ 2019-07-02T08:47:25+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_aug_12th_2.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-sets-regulatory-strategy-for-development-of-radspherin/ 2019-07-02T08:47:37+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_sept_7th_standin.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-publishes-data-explaining-radspherin-s-mechanism-of-action/ 2019-07-02T08:47:50+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/full_radspherin.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-selected-to-receive-bia-funding-from-the-research-council-of-norway/ 2019-07-02T08:48:18+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_sept_7th_standin-e1591090134293.jpg https://oncoinvent.dev2.superwp.no/pr-archive/new-radspherin-data-published/ 2019-07-02T08:48:29+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/press_release_feb-01-18.jpg https://oncoinvent.dev2.superwp.no/pr-archive/opening-of-the-radspherin-production-and-laboratory-facility/ 2019-07-02T08:48:42+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/lab_131217-1.jpg https://oncoinvent.dev2.superwp.no/pr-archive/radspherin-eu-patent-and-oi-3-antibody-us-patent-issued/ 2019-07-02T08:48:55+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/radspherin.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-a-novel-method-for-making-212pb-labeled-monoclonal-antibodies-using-a-novel-224ra-based-generator-solution/ 2019-07-02T08:49:14+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/report.png https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-is-on-the-move/ 2019-07-02T08:49:43+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/full_oncoinvent-on-the-move.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-closes-25-million-private-placement/ 2019-07-02T08:49:57+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/full_radspherin.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-strengthens-management-and-research-teams/ 2019-07-02T08:50:11+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/Illustrasjonsbilde_Ocoinvent.jpg https://oncoinvent.dev2.superwp.no/pr-archive/15-million-in-a-private-placement/ 2019-07-02T08:50:31+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_May_20th.jpg https://oncoinvent.dev2.superwp.no/pr-archive/new-board-members-at-oncoinvent-as/ 2019-07-02T08:50:46+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_aug_12th_NEW.jpg https://oncoinvent.dev2.superwp.no/pr-archive/new-chief-executive-officer/ 2019-07-02T08:51:02+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/Jan_blaa_wide.jpg https://oncoinvent.dev2.superwp.no/pr-archive/dnb-healthcare-prize-2016/ 2019-07-02T08:51:32+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_dec_15th.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-presents-radspherin-preclinical-data-at-30th-annual-congress-of-the-european-association-of-nuclear-medicine-eanm/ 2019-07-02T11:49:33+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/EANM_presentations.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-appointment-of-new-chief-financial-officer/ 2019-07-02T11:50:29+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/pr_feb_2019_new_cfo.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-receives-manufacturing-authorization-for-clinical-trial-material/ 2019-07-02T11:51:56+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/lab_131217.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-patent-issues-in-the-usa/ 2019-07-02T12:50:36+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/full_radspherin.jpg https://oncoinvent.dev2.superwp.no/wp-content/uploads/radspherin_ill.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-publication-of-standardization-model-for-activity-of-radium-224/ 2019-10-25T09:39:53+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/Applied-radiation-and-isotopes-3.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-secures-40-million-nok-financing-round-led-by-hadean-ventures/ 2020-05-19T05:00:25+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/News_sept_7th_standin-e1591090134293.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-dosing-of-first-patient-with-radspherin-in-phase-1-clinical-trial/ 2020-06-02T05:00:33+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/radspherin_bottle-e1590748690325.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-result-of-oversubscribed-repair-issue/ 2020-06-02T10:00:51+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-dosing-of-first-patient-with-radspherin-in-a-second-phase-1-clinical-trial/ 2020-06-11T11:15:06+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/radspherin_bottle-e1590748690325.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-advances-radspherin-to-second-dose-level-in-ongoing-phase-1-clinical-trial/ 2020-09-04T07:59:23+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/D85_7323_edited2-scaled.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-advances-radspherin-to-third-dose-level-in-ongoing-phase-1-clinical-trial/ 2020-10-29T09:41:48+00:00 https://oncoinvent.dev2.superwp.no/wp-content/uploads/D85_6864_hands.jpg https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-advancement-of-radspherin-to-second-dose-level-cohort-in-ongoing-phase-1-trial/ 2020-11-30T08:24:04+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-advancement-of-radspherin-to-final-dose-level-cohort-in-ongoing-rad-18-002-phase-1-trial-in-colorectal-cancer-patients/ 2021-01-11T12:01:31+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-progression-of-radspherin-to-third-dose-level-cohort-in-ongoing-rad-18-001-phase-1-trial-in-platinum-sensitive-recurrent-ovarian-cancer-patients-with-peritoneal-carcinomatos/ 2021-03-08T17:18:57+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/safety-monitoring-committee-approves-7-mbq-as-recommended-clinical-dose-for-radspherin-in-the-ongoing-rad-18-002-phase-1-trial-in-colorectal-cancer-patients/ 2021-04-09T08:30:17+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/following-a-year-of-outstanding-performance-oncoinvent-aims-to-raise-nok-150-200-million-to-move-into-efficacy-studies-with-radspherin/ 2021-06-23T07:05:03+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-secures-nok-250-m-in-an-oversubscribed-pre-ipo-funding-round/ 2021-06-29T07:54:57+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-advancement-of-radspherin-to-fourth-dose-level-cohort-in-ongoing-rad-18-001-phase-1-trial-in-ovarian-cancer-patients/ 2021-09-28T07:47:30+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-strengthens-leadership-team/ 2021-10-04T19:51:42+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-four-posters-at-the-34th-annual-congress-of-the-european-association-of-nuclear-medicine/ 2021-10-21T05:59:52+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-completion-of-enrollment-in-the-rad-18-002-phase-1-clinical-study/ 2021-11-08T08:44:41+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-appoints-adrian-senderowicz-md-to-its-board-of-directors/ 2022-02-04T13:45:53+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-participate-in-upcoming-virtual-investor-conferences/ 2022-02-15T15:30:51+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/data-from-the-ongoing-radspherin-rad-18-002-phase-1-trial-in-colorectal-cancer-patients-to-be-presented-at-the-2022-asco-annual-meeting/ 2022-05-29T19:32:01+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-initiates-radspherin-phase-2a-trial/ 2022-08-25T05:51:45+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-at-guggenheim-radiopharmaceuticals-day/ 2023-02-06T07:21:24+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-updates-phase-i-dose-escalation-completed-successfully-in-two-indications-phase-2-a-inclusion-has-started/ 2023-02-10T12:43:04+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-two-publications-in-special-edition-of-frontiers-in-medicine-focused-on-alpha-radioisotopes/ 2023-04-21T13:01:07+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/information-from-oncoinvent-as-regarding-the-newly-elected-board-members-and-the-resignation-of-ceo-jan-alfheim/ 2023-05-11T12:25:02+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-presents-15-month-safety-and-efficacy-data-from-ongoing-rad-18-002-phase-1-2a-trial-of-radspherin-in-colorectal-cancer-patients-at-the-2023-asco-annual-meeting/ 2023-06-05T12:04:16+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-at-td-cowen-radiopharmaceutical-innovation-summit/ 2023-06-16T12:11:18+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-appoints-anders-mansson-as-ceo/ 2023-07-05T12:51:50+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-initial-safety-data-from-the-phase-1-trial-of-radspherin-in-ovarian-cancer-patients-at-the-24th-congress-of-the-european-society-of-gynaecological-oncology-esgo/ 2023-09-28T13:00:28+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-presents-preliminary-18-month-safety-and-efficacy-data-from-ongoing-rad-18-002-phase-1-2a-trial-of-radspherin-in-colorectal-cancer-patients-at-the-13th-psogi-international-congress-on/ 2023-10-04T10:05:21+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-radspherin-in-colorectal-cancer-patients/ 2023-10-27T15:16:12+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-radspherin-in-ovarian-cancer-patients/ 2023-10-31T20:08:57+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-at-evercore-isi-2024-emerging-biotech-conference/ 2024-02-21T12:15:46+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-changes-to-its-board-of-directors-and-formation-of-scientific-and-clinical-advisory-board/ 2024-04-04T06:50:41+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-at-cantor-fitzgerald-frontiers-in-radiopharma-virtual-summit/ 2024-05-15T11:43:07+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-receives-fda-fast-track-designation-for-radspherin-as-treatment-for-peritoneal-carcinomatosis-from-ovarian-cancer/ 2024-06-24T05:51:11+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-appoints-oystein-soug-as-ceo/ 2024-08-28T06:58:26+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-in-ovarian-cancer-patients/ 2024-10-10T09:03:30+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-at-jonestrading-virtual-radiopharma-day/ 2024-10-25T13:47:35+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-publication-of-18-month-safety-and-efficacy-data-from-the-phase-1-2a-study-of-radspherin-in-colorectal-cancer/ 2024-11-01T13:44:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-promising-interim-results-for-radspherin-as-a-potential-treatment-for-peritoneal-carcinomatoses/ 2024-11-11T10:12:23+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-agreement-with-artbio-to-collaborate-on-radiopharma-laboratory-facilities/ 2024-12-04T15:14:51+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-announces-oversubscribed-private-placement/ 2024-12-04T22:24:11+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/final-results-of-the-subsequent-offering-and-allocation-of-offer-shares/ 2025-02-07T07:25:49+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/last-day-of-the-subscription-period-in-the-subsequent-offering/ 2025-02-07T07:28:29+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/grant-of-share-options-mandatory-notification-of-trade/ 2025-02-07T07:31:36+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/registration-of-new-share-capital/ 2025-02-18T08:49:21+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-to-present-at-various-conferences/ 2025-02-19T07:11:38+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-invitation-to-result-presentation-q4-2024/ 2025-02-20T06:46:25+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-reports-completed-inclusion-in-the-initial-safety-lead-in-cohort-of-the-phase-2-trial-of-radspherin-in-ovarian-cancer-patients/ 2025-02-27T05:56:02+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-fourth-quarter-2024-update-and-results/ 2025-02-27T08:25:49+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/mandatory-notification-of-trade/ 2025-03-05T10:00:32+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-announces-positive-safety-review-of-lead-in-cohort-advances-to-randomised-part-of-ongoing-phase-2-trial-of-radspherin-in-ovarian-cancer-patients/ 2025-03-25T06:25:49+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-reports-updated-18-month-data-from-phase-1-ovarian-cancer-trial-with-radspherin-no-new-recurrences-demonstrate-continued-promise-of-preventing-disease-progression/ 2025-04-28T06:02:28+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-invitation-to-presentation-of-q1-2025-company-update/ 2025-04-28T06:09:49+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/annual-report-2024/ 2025-04-28T18:24:58+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/minutes-from-the-annual-general-meeting-2025/ 2025-05-14T12:45:05+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-positive-final-data-from-phase-1-2a-trial-of-radspherin-in-patients-with-colorectal-peritoneal-metastases/ 2025-06-18T05:36:54+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-oncin-invitation-to-presentation-of-positive-final-data-from-phase-1-2a-trial-of-radspherin-in-patients-with-colorectal-peritoneal-metastases/ 2025-06-19T07:54:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/bergenbio-and-oncoinvent-a-rising-innovator-in-radiopharmaceutical-cancer-therapies-announce-proposed-merger-and-a-fully-underwritten-rights-issue/ 2025-06-30T20:30:42+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/announcement-of-fully-underwritten-rights-issue/ 2025-06-30T20:37:39+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-notice-of-extraordinary-general-meeting/ 2025-07-10T06:59:52+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-shareholders-approve-the-merger-plan-with-bergenbio/ 2025-08-04T12:47:07+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-invites-to-a-webcast-presentation-of-1h-2025-on-wednesday-27-august-2025/ 2025-08-22T10:40:23+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-half-yearly-report-strong-focus-on-financial-discipline-and-advancing-phase-2-program-in-ovarian-cancer/ 2025-08-27T05:05:58+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/thor-medical-and-oncoinvent-enter-strategic-thorium-228-supply-agreement/ 2025-08-29T05:44:32+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/updated-information-regarding-the-contemplated-rights-issue-and-merger/ 2025-09-17T08:45:15+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/updated-key-information-related-to-the-contemplated-rights-issue/ 2025-09-17T08:47:44+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-reports-positive-final-data-from-phase-1-trial-of-radspherin-to-treat-ovarian-cancer/ 2025-10-08T05:24:17+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/bergenbio-and-oncoinvent-key-dates-for-completion-of-merger/ 2025-10-24T06:13:59+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/bergenbio-and-oncoinvent-last-day-of-trading-in-the-shares-of-oncoinvent/ 2025-10-29T06:05:57+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-presents-final-safety-and-efficacy-results-from-the-phase-1-2a-trial-of-radspherin-to-treat-colorectal-cancer-at-the-15th-psogi-international-congress-on-peritoneal-surface-malignanci/ 2025-10-29T14:27:09+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/merger-of-bergenbio-and-oncoinvent-completed/ 2025-10-29T16:55:24+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-appoints-dr-ramzi-amri-as-new-cfo/ 2025-10-31T07:36:45+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/mandatory-notification-of-trade-2/ 2025-11-03T08:08:08+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/reminder-invitation-to-presentation-of-q3-2025-company-update-on-november-4th-2025/ 2025-11-03T12:56:46+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-updated-key-information-related-to-the-contemplated-rights-issue/ 2025-11-11T17:20:54+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-terms-of-the-underwritten-rights-issue/ 2025-11-11T17:53:16+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-ex-subscription-rights-in-rights-issue-today/ 2025-11-13T11:12:23+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-receipt-of-subscription-rights-in-the-rights-issue-by-primary-insiders-and-their-close-associates-2/ 2025-11-14T14:07:38+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-receipt-of-subscription-rights-in-the-rights-issue-by-primary-insiders-and-their-close-associates/ 2025-11-14T14:08:06+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/notice-of-extraordinary-general-meeting-in-connection-with-the-rights-issue/ 2025-11-16T10:49:52+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-commencement-of-the-subscription-period-for-the-rights-issue/ 2025-11-17T06:51:36+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-last-day-of-trading-in-subscription-rights/ 2025-11-25T06:29:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-notification-of-trade-primary-insider-close-associate/ 2025-11-27T12:07:13+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-last-day-of-the-subscription-period-in-the-rights-issue/ 2025-12-01T06:20:23+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-preliminary-results-of-the-rights-issue/ 2025-12-01T19:56:52+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-final-results-of-the-rights-issue/ 2025-12-02T12:37:41+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-notification-of-trade-primary-insider-close-associate-2/ 2025-12-02T20:49:30+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-minutes-from-extraordinary-general-meeting/ 2025-12-05T12:13:46+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-minutes-from-extraordinary-general-meeting-2/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-grant-of-share-options-to-new-cfo/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-key-information-relating-to-the-reverse-share-split-and-change-of-isin/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-new-share-capital-registered-2/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-ex-reverse-share-split-and-change-of-isin-today/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-registration-of-reverse-share-split/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/four-additional-sites-open-for-recruitment-in-oncoinvents-phase-2-trial/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-announces-webcast-presentation-of-second-half-2025-results-on-thursday-26-february-2026-2/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-to-present-positive-24-month-follow-up-data-from-phase-1-ovarian-cancer-study-of-radspherin-at-esgo-2026/ 2026-02-17T12:51:14+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-resolution-to-increase-the-share-capital-in-connection-with-settlement-of-underwriting-fee/ 2026-02-17T12:52:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-publication-of-phase-1-study-results-for-radspherin-in-ovarian-cancer-in-gynecologic-oncology/ 2026-02-17T12:52:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-notification-of-trade-primary-insider-close-associate-3/ 2026-02-17T12:52:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-new-share-capital-registered/ 2026-02-17T12:52:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-notice-of-extraordinary-general-meeting-2/ 2026-02-17T12:52:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-second-half-2025-results/ 2026-02-26T07:32:12+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-grant-of-share-options-to-the-ceo/ 2026-03-11T20:34:24+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-secures-new-patent-expanding-protection-for-radspherin/ 2026-03-19T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-annual-report-for-2025/ 2026-04-22T12:31:07+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-invitation-to-business-update-wednesday-29-april-2026/ 2026-04-23T03:00:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-notice-of-annual-general-meeting/ 2026-04-28T08:47:59+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-presents-corporate-update-in-live-webcast/ 2026-04-29T03:00:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-share-capital-decrease-completed/ 2026-05-05T06:26:10+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-minutes-from-annual-general-meeting/ 2026-05-20T07:15:41+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-grant-of-share-options-mandatory-notification-of-trade/ 2026-05-20T12:59:24+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-asa-grant-of-share-options-to-member-of-the-board-following-agm/ 2026-05-20T16:54:56+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-achieves-50-recruitment-milestone-in-phase-2-ovarian-cancer-study-of-radspherin/ 2026-06-18T03:00:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-announces-publication-of-normal-tissue-dosimetry-results-in-journal-of-nuclear-medicine/ 2026-08-11T03:00:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/invitation-to-first-half-2026-webcast-thursday-27-august-2026/ 2026-08-17T03:00:00+00:00 https://oncoinvent.dev2.superwp.no/pr-archive/oncoinvent-presents-first-half-2026-results/ 2026-08-27T03:00:00+00:00